Rafferty Asset Management
ACET icon

Rafferty Asset Management’s Adicet Bio ACET Stock Holding History

Rafferty Asset Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,377
Closed -$1.63M – 1141
2022
Q4 		$1.63M Buy
11,377
+3,158
+38% +$788K 0.01% 634
2022
Q3 		$1.87M Buy
+8,219
New +$2.09M 0.02% 522

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Rafferty Asset Management's ACET Position: Q1 2023 in Review

Rafferty Asset Management sold out of Adicet Bio (ACET) in Q1 2023, closing a stake of 11,377 shares — an estimated $1.63M sold.

Rafferty Asset Management first reported a position in ACET in Q3 2022 and held it in 2 quarters. The position peaked at $1.87M in Q3 2022. 107 funds tracked by Wall St. Rank hold ACET as of Q1 2023.

  • Rafferty Asset Management reported no remaining Adicet Bio position as of Q1 2023 after selling out during the quarter.
  • Rafferty Asset Management sold 11,377 Adicet Bio shares in Q1 2023, an estimated $1.63M.
  • Rafferty Asset Management first reported a position in Adicet Bio in Q3 2022 and held it in 2 quarters.
  • Rafferty Asset Management's Adicet Bio position peaked at $1.87M in Q3 2022.
  • 107 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2023.

Based on Rafferty Asset Management's 13F filing for Q1 2023, filed 11 May 2023.